Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Spine stereotactic radiosurgery for metastatic thyroid cancer: a single-institution experience.

Boyce-Fappiano D, Gjyshi O, Pezzi TA, Allen PK, Solimman M, Taku N, Bernstein MB, Cabanillas ME, Amini B, Tatsui CE, Rhines LD, Wang XA, Briere TM, Yeboa DN, Bishop AJ, Li J, Ghia AJ.

J Neurosurg Spine. 2020 Feb 14:1-9. doi: 10.3171/2019.12.SPINE191269. [Epub ahead of print]

PMID:
32059183
2.

Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses.

Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS.

Cancer Immunol Res. 2019 Dec;7(12):1903-1909. doi: 10.1158/2326-6066.CIR-18-0793. Epub 2019 Oct 28.

PMID:
31658994
3.

Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma.

Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG.

Surgery. 2020 Jan;167(1):80-86. doi: 10.1016/j.surg.2019.03.041. Epub 2019 Oct 21.

PMID:
31648931
4.

Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples.

Angell TE, Wirth LJ, Cabanillas ME, Shindo ML, Cibas ES, Babiarz JE, Hao Y, Kim SY, Walsh PS, Huang J, Kloos RT, Kennedy GC, Waguespack SG.

Front Endocrinol (Lausanne). 2019 Sep 11;10:612. doi: 10.3389/fendo.2019.00612. eCollection 2019.

5.

Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.

Cabanillas ME, Ryder M, Jimenez C.

Endocr Rev. 2019 Dec 1;40(6):1573-1604. doi: 10.1210/er.2019-00007.

PMID:
31322645
6.

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.

Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME.

Thyroid. 2019 Aug;29(8):1036-1043. doi: 10.1089/thy.2019.0133.

7.

Genetic profiling as a clinical tool in advanced parathyroid carcinoma.

Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL.

J Cancer Res Clin Oncol. 2019 Aug;145(8):1977-1986. doi: 10.1007/s00432-019-02945-9. Epub 2019 Jul 15.

PMID:
31309300
8.

Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features.

Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL.

J Cutan Pathol. 2019 Nov;46(11):872-877. doi: 10.1111/cup.13536. Epub 2019 Jul 15.

PMID:
31254410
9.

Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.

Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM.

Head Neck. 2019 Jun;41(6):1928-1934. doi: 10.1002/hed.25634. Epub 2019 Feb 13.

PMID:
30758123
10.

Bilateral spontaneous pneumothoraces in anaplastic thyroid cancer.

Kazzaz FI, Cabanillas ME, Bashoura L, Shannon VR, Faiz SA.

Respir Med Case Rep. 2019 Jan 8;26:197-199. doi: 10.1016/j.rmcr.2019.01.006. eCollection 2019.

11.

Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.

Cabanillas ME, Takahashi S.

Semin Oncol. 2019 Feb;46(1):57-64. doi: 10.1053/j.seminoncol.2018.11.004. Epub 2018 Dec 21. Review.

12.

Anaplastic Thyroid Carcinoma with Gastric Metastasis.

Chavez AAL, Iyer P, Cazacu IM, Cabanillas ME, Rashid A, Bhutani MS.

Curr Health Sci J. 2018 Jul-Sep;44(3):294-298. doi: 10.12865/CHSJ.44.03.14. Epub 2018 Jul 15.

13.

Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules.

Ye W, Hannigan B, Zalles S, Mehrotra M, Barkoh BA, Williams MD, Cabanillas ME, Edeiken-Monroe B, Hu P, Duose D, Wistuba II, Medeiros LJ, Stewart J, Luthra R, Roy-Chowdhuri S.

Cancer Cytopathol. 2019 Mar;127(3):146-160. doi: 10.1002/cncy.22098. Epub 2019 Jan 8.

14.

The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells.

Puli OR, Danysh BP, McBeath E, Sinha DK, Hoang NM, Powell RT, Danysh HE, Cabanillas ME, Cote GJ, Hofmann MC.

Neoplasia. 2018 Nov;20(11):1121-1134. doi: 10.1016/j.neo.2018.09.003. Epub 2018 Sep 25.

15.

Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond.

Rao SN, Cabanillas ME.

J Endocr Soc. 2018 Aug 13;2(10):1109-1130. doi: 10.1210/js.2018-00180. eCollection 2018 Oct 1. Review.

16.

Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions.

Tam S, Boonsripitayanon M, Amit M, Fellman BM, Li Y, Busaidy NL, Cabanillas ME, Dadu R, Sherman S, Waguespack SG, Williams MD, Goepfert RP, Gross ND, Perrier ND, Sturgis EM, Zafereo ME.

Thyroid. 2018 Oct;28(10):1301-1310. doi: 10.1089/thy.2017.0572.

PMID:
30141373
17.

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.

Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R.

Thyroid. 2018 Oct;28(10):1243-1251. doi: 10.1089/thy.2018.0116.

18.

Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.

Jaber T, Waguespack SG, Cabanillas ME, Elbanan M, Vu T, Dadu R, Sherman SI, Amit M, Santos EB, Zafereo M, Busaidy NL.

J Clin Endocrinol Metab. 2018 Oct 1;103(10):3698-3705. doi: 10.1210/jc.2018-00612.

19.

Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer?

Amit M, Boonsripitayanon M, Goepfert RP, Tam S, Busaidy NL, Cabanillas ME, Dadu R, Varghese J, Waguespack SG, Gross ND, Graham P, Williams MD, Sturgis EM, Zafereo ME.

Ann Surg Oncol. 2018 Oct;25(11):3380-3388. doi: 10.1245/s10434-018-6563-x. Epub 2018 Jul 18.

PMID:
30022274
20.

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.

Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME.

J Immunother Cancer. 2018 Jul 11;6(1):68. doi: 10.1186/s40425-018-0378-y.

21.

Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer.

Tam S, Amit M, Boonsripitayanon M, Busaidy NL, Cabanillas ME, Waguespack SG, Gross ND, Grubbs EG, Williams MD, Lai SY, Sturgis EM, Zafereo ME.

Thyroid. 2018 Aug;28(8):982-990. doi: 10.1089/thy.2017.0513. Epub 2018 Jul 27.

PMID:
29936892
22.

Selective RET kinase inhibition for patients with RET-altered cancers.

Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A.

Ann Oncol. 2018 Aug 1;29(8):1869-1876. doi: 10.1093/annonc/mdy137.

23.

Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma.

Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M.

Thyroid. 2018 Jul;28(7):945-951. doi: 10.1089/thy.2018.0060. Epub 2018 Jun 29.

24.

Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy.

Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MD.

Mol Cancer Ther. 2018 Jul;17(7):1575-1584. doi: 10.1158/1535-7163.MCT-17-0871. Epub 2018 Apr 25.

25.

Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma.

Smith AL, Williams MD, Stewart J, Wang WL, Krishnamurthy S, Cabanillas ME, Roy-Chowdhuri S.

Cancer Cytopathol. 2018 Jun;126(6):406-413. doi: 10.1002/cncy.21992. Epub 2018 Mar 26.

26.

Recent advances and emerging therapies in anaplastic thyroid carcinoma.

Cabanillas ME, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL.

F1000Res. 2018 Jan 18;7. pii: F1000 Faculty Rev-87. doi: 10.12688/f1000research.13124.1. eCollection 2018. Review.

27.

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH.

Clin Cancer Res. 2018 Apr 1;24(7):1546-1553. doi: 10.1158/1078-0432.CCR-17-2297. Epub 2018 Jan 4.

28.

Imaging of Anaplastic Thyroid Carcinoma.

Ahmed S, Ghazarian MP, Cabanillas ME, Zafereo ME, Williams MD, Vu T, Schomer DF, Debnam JM.

AJNR Am J Neuroradiol. 2018 Mar;39(3):547-551. doi: 10.3174/ajnr.A5487. Epub 2017 Dec 14.

29.

Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.

Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F.

Mol Cancer Ther. 2018 Mar;17(3):671-676. doi: 10.1158/1535-7163.MCT-17-0673. Epub 2017 Dec 13.

30.

Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer.

Amit M, Tam S, Boonsripitayanon M, Cabanillas ME, Busaidy NL, Grubbs EG, Lai SY, Gross ND, Sturgis EM, Zafereo ME.

JAMA Otolaryngol Head Neck Surg. 2018 Feb 1;144(2):108-114. doi: 10.1001/jamaoto.2017.2416. Erratum in: JAMA Otolaryngol Head Neck Surg. 2019 May 1;145(5):484.

31.

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.

Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME.

Thyroid. 2018 Jan;28(1):79-87. doi: 10.1089/thy.2017.0285. Epub 2017 Dec 21.

32.

Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer.

Tam S, Amit M, Boonsripitayanon M, Cabanillas ME, Busaidy NL, Gunn GB, Lai SY, Gross ND, Sturgis EM, Zafereo ME.

JAMA Otolaryngol Head Neck Surg. 2017 Dec 1;143(12):1244-1251. doi: 10.1001/jamaoto.2017.2077. No abstract available.

33.

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B.

J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26.

34.

Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer.

Pena I, Clayman GL, Grubbs EG, Bergeron JM Jr, Waguespack SG, Cabanillas ME, Dadu R, Hu MI, Fellman BM, Li Y, Gross ND, Lai SY, Sturgis EM, Zafereo ME.

Head Neck. 2018 Jan;40(1):79-85. doi: 10.1002/hed.24969. Epub 2017 Oct 16.

PMID:
29044788
35.

Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.

Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3591-3599. doi: 10.1210/jc.2017-01039.

36.

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.

Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH.

J Clin Oncol. 2017 Oct 10;35(29):3315-3321. doi: 10.1200/JCO.2017.73.0226. Epub 2017 Aug 17.

37.

Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.

Voss RK, Feng L, Lee JE, Perrier ND, Graham PH, Hyde SM, Nieves-Munoz F, Cabanillas ME, Waguespack SG, Cote GJ, Gagel RF, Grubbs EG.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2807-2813. doi: 10.1210/jc.2017-00317.

38.

Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer.

Cabanillas ME, Williams MD, Gunn GB, Weitzman SP, Burke L, Busaidy NL, Ying AK, Yiin YH, William WN, Lu C, Lai SY.

Head Neck. 2017 Jul;39(7):1291-1295. doi: 10.1002/hed.24784. Epub 2017 Apr 28. Review.

PMID:
28452157
39.

Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.

Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME.

Thyroid. 2017 May;27(5):672-681. doi: 10.1089/thy.2016.0395. Epub 2017 Feb 16.

40.

Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base.

Pezzi TA, Mohamed ASR, Sheu T, Blanchard P, Sandulache VC, Lai SY, Cabanillas ME, Williams MD, Pezzi CM, Lu C, Garden AS, Morrison WH, Rosenthal DI, Fuller CD, Gunn GB.

Cancer. 2017 May 1;123(9):1653-1661. doi: 10.1002/cncr.30493. Epub 2016 Dec 27.

41.

Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer.

Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA Jr, Cote GJ, Sherman SI.

J Clin Endocrinol Metab. 2016 Nov;101(11):4461-4467. Epub 2016 Aug 30.

42.

Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.

Grubbs EG, Williams MD, Scheet P, Vattathil S, Perrier ND, Lee JE, Gagel RF, Hai T, Feng L, Cabanillas ME, Cote GJ.

Thyroid. 2016 Nov;26(11):1553-1562. Epub 2016 Oct 18.

43.

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.

Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS.

Clin Cancer Res. 2017 Mar 15;23(6):1388-1396. doi: 10.1158/1078-0432.CCR-16-1432. Epub 2016 Sep 20.

44.

Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.

Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas ME.

Thyroid. 2017 Jan;27(1):81-87. doi: 10.1089/thy.2016.0076. Epub 2016 Nov 29.

45.

Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.

Xu JY, Murphy WA Jr, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI.

J Clin Endocrinol Metab. 2016 Dec;101(12):4871-4877. Epub 2016 Sep 23.

46.

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.

Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ.

Lancet Oncol. 2016 Sep;17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23.

47.

Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy.

Cabanillas ME, Zafereo M, Gunn GB, Ferrarotto R.

J Oncol Pract. 2016 Jun;12(6):511-8. doi: 10.1200/JOP.2016.012013. Review.

PMID:
27288464
48.

Thyroid cancer.

Cabanillas ME, McFadden DG, Durante C.

Lancet. 2016 Dec 3;388(10061):2783-2795. doi: 10.1016/S0140-6736(16)30172-6. Epub 2016 May 27. Review.

PMID:
27240885
49.

Letter to the Editor regarding squamoid pattern of anaplastic thyroid carcinoma, a poorly recognized entity.

Cabanillas ME, Williams MD.

Head Neck. 2016 Aug;38(8):1290. doi: 10.1002/hed.24503. Epub 2016 May 19. No abstract available.

PMID:
27198734
50.

Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.

Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann MC.

Oncotarget. 2016 May 24;7(21):30907-23. doi: 10.18632/oncotarget.9023.

Supplemental Content

Loading ...
Support Center